NEW DELHI: Biocon Biologics, a subsidiary of Biocon has signed a distribution settlement with Sandoz, granting the corporate unique rights to advertise, promote and distribute `Adalimumab BS for subcutaneous injection [FKB]’* in Japan.
Primarily based on this, Viatris has accomplished advertising and marketing and promotion of the product as of December 15, however will proceed to supply transition assist till Sandoz will step by step assume duties for the product beginning February 15, 2024, an organization assertion stated.
Biocon Biologics has acquired the worldwide biosimilars portfolio of Viatris together with Adalimumab. Fujifilm Kyowa Kirin Biologics, the developer of the drug, has concluded an unique international advertising and marketing license settlement with Biocon Biologics affiliate.
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira and is indicated for immune-related illnesses corresponding to rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn’s illness, and ulcerative colitis.
Sandoz is dedicated to additional strengthening its product pipeline to drive sustainable enterprise progress. The switch of the distribution rights of this product is a part of this technique, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Primarily based on this, Viatris has accomplished advertising and marketing and promotion of the product as of December 15, however will proceed to supply transition assist till Sandoz will step by step assume duties for the product beginning February 15, 2024, an organization assertion stated.
Biocon Biologics has acquired the worldwide biosimilars portfolio of Viatris together with Adalimumab. Fujifilm Kyowa Kirin Biologics, the developer of the drug, has concluded an unique international advertising and marketing license settlement with Biocon Biologics affiliate.
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira and is indicated for immune-related illnesses corresponding to rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn’s illness, and ulcerative colitis.
Sandoz is dedicated to additional strengthening its product pipeline to drive sustainable enterprise progress. The switch of the distribution rights of this product is a part of this technique, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
